Sanofi Makes Big Strides In Eradicating Sleeping Sickness
Acoziborole Cured 95% of People With Late-Stage Disease
Executive Summary
The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.
You may also be interested in...
Sanofi Puts Faith In Rare Review Procedure For ‘Breakthrough’ Sleeping Sickness Drug
Sanofi believes its fully oral sleeping sickness treatment, fexinidazole, will support efforts to eliminate the disease by 2020. The European Medicines Agency is set to start reviewing the product soon with a view to it being used in Africa.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.